Glenmark Pharma, SaNOtize Research launch nasal spray for COVID-19 treatment

Glenmark Pharmaceuticals and its partner Canadian biotech firm SaNOtize Research on Wednesday launched Nitric Oxide nasal spray for the treatment of adult patients with COVID-19, who have a high risk of progression of the disease.

The partners have introduced the product in India under the brand name FabiSpray. The Mumbaibased drug firm had earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for the Nitric Oxide nasal spray (NONS) as part of the accelerated approval process. FabiSpray is designed to kill the COVID-19 virus in the upper airways.

The company stated that it has proven anti-microbial properties with a direct virucidal effect on SARSCoV-2. NONS, when sprayed over nasal mucosa, acts as a physical and chemical barrier against the virus, preventing it from incubating and spreading to the lungs.

“As a leading pharma player, it is important that we are an integral part of India’s fight against the pandemic. We are happy to receive approval for Nitric Oxide Nasal Spray (FabiSpray) and launch it in partnership with SaNOtize.

“This reaffirms our commitment of providing another antiviral treatment for COVID-19, and we are confident that it will offer patients a much needed therapy option,” Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals said.

In July 2021, Glenmark had entered into a partnership with Canadian biotech firm SaNOtize to manufacture and distribute its Nitric Oxide Nasal Spray for COVID-19 in India.